← Markets

ACADIA Pharmaceuticals Inc.

ACAD · NASDAQ

Market closed$25.60$-0.030000 (-0.12%)After hours $26.00 · +1.56%

Key statistics

Previous close$25.63
Open$25.21
Day high$25.84
Day low$25.20
52-week high$28.35
52-week low$19.69
Market cap4.38B
Volume1.14M
Average volume1.59M
P/E ratio12.55
Forward P/E46.59
EPS2.04
Dividend yield0.00%

Market context

Why it moved

ACAD shares edged lower amid a broad risk-off market environment driven by escalating U.S.-Iran tensions, a semiconductor selloff weighing on global equities, and rising volatility, with no company-specific catalysts to offset the general market pressure.

YoutubeStockinvestRiotimesonlineLitefinanceMufgresearch

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026ACADIA Pharmaceuticals closed essentially flat, trading in line with a cautious broader market as tech-driven selloffs weighed on equities and the healthcare sector ETF (XLV) also edged lower. Investor focus is turning to the company's upcoming Q2 2026 earnings report, scheduled for August 4 after market close, which will be a key catalyst. In after-hours trading, ACAD shares are gaining over 1.5%, outperforming XLV's modest after-hours uptick of 0.19%, as sector sentiment improves amid UBS upgrading healthcare as a key allocation—citing improving fundamentals, a stabilizing regulatory environment, and biotech M&A tailwinds.

-0.1171

July 16, 2026ACADIA Pharmaceuticals closed modestly higher as investors look ahead to its Q2 2026 earnings call scheduled for August 4, with the company announcing the date on July 15. The gain came amid a broadly supportive macro backdrop — softer-than-expected June CPI data eased rate-hike fears — and growing UBS-highlighted optimism toward the biotech sector, which is seen benefiting from M&A tailwinds and product catalysts. Analyst consensus points to a $32.94 price target, implying meaningful upside, while ACADIA's strong net margin of 34.3% and 96.7% institutional ownership underscore its established commercial profile.

1.6869

July 14, 2026ACADIA Pharmaceuticals fell nearly 3%, underperforming the broader healthcare sector (XLV edged lower), as broader macro headwinds—rising oil prices and renewed U.S.-Iran tensions—weighed on equities. The pullback comes after a strong ~23% surge over the prior month fueled by the EMA's CHMP positive opinion recommending EU marketing authorization for DAYBU (trofinetide) for Rett syndrome, which would make it the first approved therapy in the EU for the condition. Adding some near-term caution, ACADIA's Principal Accounting Officer disclosed the sale of nearly half his shares, while RBC Capital recently boosted its price target to $36 from $29 (Outperform), and analysts broadly view the stock as trading at a discount to fair value.

-2.746

July 11, 2026ACADIA Pharmaceuticals closed modestly lower in the regular session but edged back up in after-hours trading, with the stock continuing to attract attention amid a broader biotech momentum wave. A fresh valuation analysis highlighted that ACAD trades at just 11.9x earnings — well below the biotech industry average of 17.5x and a peer average of 62.1x — screening as undervalued even after a ~21% gain over the past year. The bullish backdrop for biotech broadly, with Jim Cramer calling it "the hottest group in the market" and the XBI approaching multi-year highs, adds further context for investor interest, though looming Medicaid cuts under the One Big Beautiful Bill could weigh on future revenue projections.

-0.7194

July 8, 2026ACADIA Pharmaceuticals closed higher, buoyed by a bullish analyst action as RBC Capital raised its price target to $36 from $29 while maintaining an Outperform rating, signaling growing confidence in the company's pipeline and commercial prospects. The move adds to a constructive analyst backdrop — Canaccord previously reiterated its Buy rating and $32 target, noting ACAD remains undervalued on approved products alone — while Jim Cramer's call that biotech is "the hottest group in the market" amid an anticipated M&A wave provided additional sector-level tailwinds. ACADIA also named Carl Segerstrom as Chief People Officer, signaling organizational investment ahead of its next growth phase.

1.6686

July 7, 2026ACADIA Pharmaceuticals edged lower amid a mixed session for healthcare, even as the broader market rallied on semiconductor strength. The company's headline news of the day was the appointment of Carl Segerstrom as Chief People Officer, a leadership addition aimed at supporting growth as ACADIA positions itself as a leading neurological and rare disease company. Analyst sentiment remains constructive, with Canaccord maintaining a Buy rating and $32 price target following Q1 results, citing the stock as undervalued and flagging the upcoming remlifanserin readout as an underappreciated pipeline catalyst.

-0.7701

July 3, 2026ACADIA Pharmaceuticals closed up roughly 3% on July 2, benefiting from a broad-based healthcare sector rally that made healthcare the strongest-gaining S&P 500 sector on the day. The gains came alongside a softer-than-expected U.S. June jobs report (only 57,000 jobs added), which eased Federal Reserve rate-hike fears and provided a macro tailwind for defensive healthcare names — with the sector ETF XLV closing near its 52-week high. In after-hours trading, ACAD shares slipped modestly, giving back a portion of the session's advance.

3.0556

July 1, 2026ACADIA Pharmaceuticals edged down in after-hours trading, consolidating after surging roughly 15% last Thursday — its best session in over a year — when the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Daybue for Rett syndrome upon re-examination, reversing a negative opinion issued in February. If approved by the European Commission, Daybue would become the first EU-approved treatment for Rett syndrome, expanding on its existing approvals in the U.S., Canada, and Israel, and lifting investor optimism around a potential acquisition target.

-0.3953

Simply Wall Street · July 9, 2026ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% RunStock Titan · July 6, 2026Acadia taps 25-year HR veteran for chief people officer roleSeeking Alpha · June 29, 2026Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In FocusPluang · June 29, 2026Acadia Pharmaceuticals shows steady growth with Nuplazid and Daybue, eyes high-risk Alzheimer's drug catalyst.BioPharma Dive · June 26, 2026On second try, Acadia drug gets nod from European regulators
Benzinga · July 7, 2026RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36
Mt Newswire · July 7, 2026RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating
Benzinga · June 30, 2026B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30
Benzinga · June 29, 2026Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $35
Benzinga · June 29, 2026Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36
Mt Newswire · June 29, 2026Deutsche Bank Raises Price Target on ACADIA Pharmaceuticals to $37 From $32, Keeps Buy Rating
Benzinga · June 26, 2026Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
Mt Newswire · June 26, 2026Acadia Pharmaceuticals' Daybu Wins Positive Opinion From EU Regulator; Shares Rise

Peers

S&P 500SPX · $7,457.69-1.01%Neurocrine Biosciences, Inc.NBIX · $170.88-0.39%Supernus Pharmaceuticals, Inc.SUPN · $48.04-0.35%Alkermes plcALKS · $52.72+1.50%Jazz Pharmaceuticals plcJAZZ · $247.53+2.21%BioMarin Pharmaceutical Inc.BMRN · $59.59-0.68%Catalyst Pharmaceuticals, Inc.CPRX · $31.490.00%Denali Therapeutics Inc.DNLI · $23.29+2.46%Ascendis Pharma A/SASND · $261.00+0.46%BridgeBio Pharma, Inc.BBIO · $81.38+1.34%Omeros CorporationOMER · $9.69+5.10%Alector, Inc.ALEC · $1.50+2.04%